Multi-omic drug discovery

Scientists at the John van Geest Cancer Research Centre study epithelial-mesenchymal transition (EMT) to find new therapeutic targets for metastatic prostate cancer.

06 / 30 / 2021 | David Boocock

Prostate cancer is the most common male cancer in Europe and the US, and mortality is most often the result of metastasis. Dr. David Boocock discusses one of the projects at his research center, which is to find new therapeutic targets for treating metastatic prostate cancer. Scientists created a cell culture model to gain insight into EMT and identify targets, employing quantitative mass spectrometry for gene expression profiling and proteomic profiling along the way.

“So, if you can get a handle on this, as most cancer researchers know, there’s a good opportunity here for modulating and stopping the spread of cancer.”

David Boocock